Live feed08:00:00·29mPRReleasevia QuantisnowAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One WeekByQuantisnow·Wall Street's wire, on your screen.ANNX· Annexon Inc.Health Care
